Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
activityin, amassed, appeal, apple, ATM, attorney, biology, Black, blood, butpari, callicutt, checkpoint, commonly, Continental, coupled, diabetic, EACRI, Earl, Earle, Eli, Escrow, expert, extinguishment, Fast, Foley, forward, Gillett, Harold, heard, imaging, immunogenic, immunologic, immunology, inhibitory, inin, intermediate, ipilimumab, irRECIST, jack, leaving, led, LICR, LLC, LLP, lymphocyte, Maureen, McGladrey, memory, MLV, Mottern, neoplastic, nitric, onForm, oral, orally, Oregon, oxide, paragraph, passu, pectin, Portland, preceding, prostate, rationale, Redmond, sarcoma, secretary, semiannually, Shlevin, site, sponsorship, Subtopic, synthase, threatening, Trust, unregistered, Walker, William, Zealand, Zomer
Filing tables
Filing exhibits
Related press release
GALT similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in Registration Statement Nos. 333-176306, 333-176305, 333-116629, 333-109893 and 333-159247 on Form S-8, and Registration Nos. 333-169463, 333-172849, 333-150898, 333-148911, 333-132459, 333-118907, 333-115118, 333-111650, and 333-109887 on Form S-3, of our report dated March 20, 2014 relating to our audit of the consolidated financial statements, which appear in this Annual Report on Form 10-K of Galectin Therapeutics, Inc. for the year ended December 31, 2013.
/s/ McGladrey LLP
Charlotte, North Carolina
March 21, 2014